Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells

Biomolecules(2022)10.3390/biom12040531Source: DataRank Database

A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells is a research paper published in Biomolecules (2022). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.54)OA: goldTopics (55)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Prasad Thangavelu,Renee M. Terrell,Bridg’ette Israel,A. Sarkar ORCID,A. Michael Davidson ORCID

Live enrichment

PubMed:35454120 PMC:PMC9024838 OpenAlex:https://openalex.org/W4221031812

National Institutes of Health

Grant: SC1GM125617

National Institutes of Health

Grant: U54MD007582

National Science Foundation

Grant: 1824267

FAMU ADVANCE IT: Using Cultural Humility to Balance the Institutional and Intersectional Barriers to Equity for STEM Faculty

NIMHD NIH HHS

Grant: U54 MD007595

National Institutes of Health

Grant: 5SC1GM125617-02

Second line breast cancer therapy alters aromatase inhibitor resistant metastasis

National Institutes of Health

Grant: 5U54MD007582-37

FAMU Center for Health Disparities Research

FWCI

0.54

Citation Percentile

0.6%

Citation Trend

2022

2023

2024

goldLicense: cc-by

journalhttps://www.mdpi.com/2218-273X/12/4/531/pdf?version=1648806779

publisherhttps://www.mdpi.com/2218-273X/12/4/531/pdf?version=1648806779

publisherhttps://www.mdpi.com/2218-273X/12/4/531/pdf

journalhttps://doi.org/10.3390/biom12040531

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35454120

Fields of Study

Microtubule and mitosis dynamicsCancer-related Molecular PathwaysCancer Cells and Metastasis0301 basic medicine0303 health sciences03 medical and health sciencesApoptosisCell Cycle ProteinsCell Line, TumorCell ProliferationHumansProtein Serine-Threonine KinasesProto-Oncogene ProteinsTriple Negative Breast NeoplasmsPolo-Like Kinase 1

MeSH Terms

Polo-Like Kinase 1HumansProto-Oncogene ProteinsApoptosisProtein Serine-Threonine KinasesCell Cycle ProteinsCell Line, TumorCell ProliferationTriple Negative Breast Neoplasms

Keywords

Allosteric regulationPLK1Triple-negative breast cancerCancer researchKinaseCell cycleChemistryCancer cellCell cycle checkpointViability assayCell growthCancerBreast cancerCellBiologyEnzymeBiochemistryPolo-like kinase 1Allosteric InhibitorMammospheresApoptosisCell Cycle ProteinsTriple Negative Breast NeoplasmsProtein Serine-Threonine KinasesMicrobiologyQR1-502ArticleCell Line, TumorProto-Oncogene ProteinsHumansCell Proliferation

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells

FAIR Checklist

Authors (9)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)